AI might improve healthcare for some, not all

AI in healthcare has long been touted as an innovative technology that will accelerate care treatments and even replace some tasks performed by clinicians.

However, all of AI’s saving graces may not affect patient populations equally if the tool “tramples patient privacy rights, overlooks biases and limitations, or fails to deploy services in a way that improves health outcomes for most people,” writes Jeremy Hsu for Smithsonian.com.

So far, AI capabilities are enjoined with human interactions in healthcare. In other words, AI has yet to replace humans in the healthcare system and “AI can’t go it alone,” according to Hsu.

Following AI models blindly, which are lacking general human intelligence, can lead to other risks, especially if a model can’t consider unusual data points. This is especially true of new populations. In addition, the disparities in access to healthcare across the world could be exacerbated by AI, which could either help or make these inequities worse.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.